Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Why Cyclin E1 biomarker targeting may become central to next-generation ovarian cancer therapies Find out why Zentalis Pharmaceuticals’ Cyclin E1 strategy could reshape ovarian cancer treatment and investor sentiment into 2026. bySoujanya RaviApril 12, 2026